In previous studies, we had found that the peptidases ANPEP and DPP‐4, a well‐known drug target for T2D, were associated with NAFLD in a human cohort and mouse models (Niu et al, 2019), and we found them to be significantly and substantially upregulated upon HSC activation (Fig 6F). The gene discussed is ANPEP; the disease is metabolic dysfunction-associated steatotic liver disease.